The Journal of Urology
Volume 171, Issue 2, Supplement , Pages S41-S44 , February 2004

Novel Therapeutic Molecular Targets for Prostate Cancer: The mTor Signaling Pathway and Epidermal Growth Factor Receptor

REFERENCES 

  1. Debes JD , Schmidt LJ , Huang H , Tindall DJ . P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6 . Cancer Res . 2002;62:5632
  2. Heber D , Lu QY . Overview of mechanisms of action of lycopene . Exp Biol Med . 2002;227:920
  3. Mercader M , Bodner BK , Moser MT , Kwon PS , Park ES , Manecke RG , et al.   T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer . Proc Natl Acad Sci USA . 2001;98:14565
  4. Nelson WG , DeWeese TL , DeMarzo AM . The diet, prostate inflammation, and the development of prostate cancer . Cancer Metastasis Rev . 2002;21:3
  5. Twillie DA , Eisenberger MA , Carducci MA , Hseih WS , Kim WY , Simons JW . Interleukin-6: a candidate mediator of human prostate cancer morbidity . Urology . 1995;45:542
  6. Burroughs KD , Oh J , Barrett JC , DiAugustine RP . Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1? . Mol Cancer Res . 2003;1:312
  7. Chan JM , Stampfer MJ , Giovannucci E , Gann PH , Ma J , Wilkinson P , et al.   Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study . Science . 1998;279:563
  8. Signorello LB , Brismar K , Bergstrom R , Andersson SO , Wolk A , Trichopoulos D , et al.   Insulin-like growth factor-binding protein-1 and prostate cancer . J Natl Cancer Inst . 1999;91:1965
  9. Whang YE , Wu X , Suzuki H , Reiter RE , Tran C , Vessella RL , et al.   Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression . Proc Natl Acad Sci USA . 1998;95:5246
  10. Li J , Yen C , Liaw D , Podsypanina K , Bose S , Wang SI , et al.   PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer . Science . 1997;275:1943
  11. McMenamin ME , Soung P , Perera S , Kaplan I , Loda M , Sellers WR . Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage . Cancer Res . 1999;59:4291
  12. Vivanco I , Sawyers CL . The phosphatidylinositol 3-Kinase AKT pathway in human cancer . Nat Rev Cancer . 2002;2:489
  13. Feilotter HE , Nagai MA , Boag AH , Eng C , Mulligan LM . Analysis of PTEN and the 10q23 region in primary prostate carcinomas . Oncogene . 1998;16:1743
  14. Paweletz CP , Charboneau L , Bichsel VE , Simone NL , Chen T , Gillespie JW , et al.   Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front . Oncogene . 2001;20:1981
  15. Malik SN , Brattain M , Ghosh PM , Troyer DA , Prihoda T , Bedolla R , et al.   Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer . Clin Cancer Res . 2002;8:1168
  16. Kwabi-Addo B , Giri D , Schmidt K , Podsypanina K , Parsons R , Greenberg N , et al.   Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression . Proc Natl Acad Sci USA . 2001;98:11563
  17. Hidalgo M , Rowinsky EK . The rapamycin-sensitive signal transduction pathway as a target for cancer therapy . Oncogene . 2000;19:6680
  18. Neshat MS , Mellinghoff IK , Tran C , Stiles B , Thomas G , Petersen R , et al.   Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR . Proc Natl Acad Sci USA . 2001;98:10314
  19. Guba M , von Breitenbuch P , Steinbauer M , Koehl G , Flegel S , Hornung M , et al.   Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor . Nat Med . 2002;8:128
  20. Dancey JE . Clinical development of mammalian target of rapamycin inhibitors . Hematol Oncol Clin North Am . 2002;16:1101
  21. Harper ME , Glynne-Jones E , Goddard L , Mathews P , Nicholson RI . Expression of androgen receptor and growth factors in premalignant lesions of the prostate . J Pathol . 1998;186:169
  22. Leav I , McNeal JE , Ziar J , Alroy J . The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartments of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions . Hum Pathol . 1998;29:668
  23. Scher HI , Sarkis A , Reuter V , Cohen D , Netto G , Petrylak D , et al.   Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms . Clin Cancer Res . 1995;1:545
  24. Hackel PO , Zwick E , Prenzel N , Ullrich A . Epidermal growth factor receptors: critical mediators of multiple receptor pathways . Curr Opin Cell Biol . 1999;11:184
  25. Mendelsohn J . Targeting the epidermal growth factor receptor for cancer therapy . J Clin Oncol . 2002;20(suppl.):1S
  26. Needle MN . Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody . Semin Oncol . 2002;29(suppl.):55
  27. Kies MS , Harari PM . Cetuximab (Imclone/Merck/Bristol-Myers Squibb) . Curr Opin Investig Drugs . 2002;3:1092
  28. de Bono JS , Rowinsky EK . The ErbB receptor family: a therapeutic target for cancer . Trends Mol Med . 2002;8(suppl.):S19

PII: S0022-5347(05)62517-7

doi: 10.1097/01.ju.0000108100.53239.b7

The Journal of Urology
Volume 171, Issue 2, Supplement , Pages S41-S44 , February 2004

Article Tools